Caricamento...

Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines

The inhibitory epidermal growth factor receptor (EGFR) antibody, cetuximab, is an approved therapy for head and neck squamous cell carcinoma (HNSCC). Despite tumor response observed in some HNSCC patients, cetuximab alone or combined with radio- or chemotherapy fails to yield long-term control or cu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Pharmacol
Autori principali: Hinz, Trista K., Kleczko, Emily K., Singleton, Katherine R., Calhoun, Jacob, Marek, Lindsay A., Kim, Jihye, Tan, Aik Choon, Heasley, Lynn E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: The American Society for Pharmacology and Experimental Therapeutics 2019
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7385532/
https://ncbi.nlm.nih.gov/pubmed/31554698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.119.117804
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !